Suppr超能文献

前列腺癌的新型治疗策略:在靶向试验中建立患者选择分层系统。

Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.

作者信息

Priolo Carmen, Oh William K, Loda Massimo

机构信息

Harvard Medical School, Brigham and Women's Hospital, Department of Pathology, 44 Binney Street, D1537, Boston, MA 02115, USA.

出版信息

IDrugs. 2009 Mar;12(3):165-8.

Abstract

Currently, the standard treatment for metastatic hormone-refractory prostate cancer includes a combination regimen with docetaxel and prednisone. Although such therapy has been demonstrated to improve survival compared with previous standards of treatment, the regimen is not curative. In efforts to identify alternative therapeutic strategies that would target single or multiple pathways activated in cancer, many small-molecule inhibitors and recombinant humanized mAbs have been tested in the preclinical setting, and many of these compounds have entered phase I/II clinical trials. However, no guidelines for the use of these drugs are available to date. Results from clinical trials are often difficult to interpret, primarily as a result of the lack of a molecular characterization of prostate tumors; such characterization would help in the search for predictive markers of response to specific drugs. Thus, a molecular classification of human prostate tumors is actively sought to assess predictive models for the stratification of patients with metastatic prostate cancer who are participating in targeted clinical trials.

摘要

目前,转移性激素难治性前列腺癌的标准治疗包括多西他赛和泼尼松联合方案。尽管与先前的治疗标准相比,这种疗法已被证明可提高生存率,但该方案并非治愈性的。为了确定针对癌症中激活的单一或多种途径的替代治疗策略,许多小分子抑制剂和重组人源化单克隆抗体已在临床前环境中进行了测试,其中许多化合物已进入I/II期临床试验。然而,迄今为止尚无这些药物的使用指南。临床试验的结果往往难以解释,主要原因是缺乏前列腺肿瘤的分子特征;这种特征将有助于寻找对特定药物反应的预测标志物。因此,人们正在积极寻求对人类前列腺肿瘤进行分子分类,以评估参与靶向临床试验的转移性前列腺癌患者分层的预测模型。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验